Nariman Mehta
| Nariman Bomanshaw Mehta | |
|---|---|
 Nariman Bomanshaw Mehta | |
| Born |
April 20, 1920 Bombay, India |
| Died |
August 22, 2014 (aged 94)[1] Burlington, NC |
| Citizenship | United States |
| Nationality | United States |
| Fields | Organic chemistry |
| Institutions | Seagram, GlaxoSmithKline |
| Alma mater | St. Xavier's College, Mumbai, University of Kansas |
| Known for | Synthesis of antidepressant drug Bupropion (marketed as Wellbutrin) |
| Spouse | Barbara DeShane |
| Children | 2 daughters, 1 son |
Nariman Bomanshaw Mehta (April 8, 1920 – August 22, 2014)[1] was an Indian-born American organic chemist and pharmacologist who designed, synthesized, and patented the organic compound Bupropion, marketed under the name Wellbutrin as an antidepressant and smoking cessation aid.[2]
Early life and education
Mehta was born in Bombay, India. He attended St. Xavier's College in Bombay, from where he received Bachelor of Science degrees in chemistry and physics and Bachelor of Arts degrees in English and economics, and a Master of Science degree. In 1939, he and a fellow student K. D. Irani wrote and published the book “Textbook of Theoretical and Practical Physics”.[3]
Mehta won a Tata Scholarship and received a grant from Wendell Willkie. In 1947 Mehta went to the United States, where he earned a PhD in chemistry from The University of Kansas.
He had two daughters and a son.
Career
Seagram invited Mehta to the United States as a trainee in their research lab where he learnt about fermentation and distillation. During his time at Seagram, Mehta studied the antibiotic Penicillin. While teaching chemistry at Central State University, Wilberforce, Ohio, Mehta joined the pharmaceutical company Burroughs Wellcome, Inc., now GlaxoSmithKline, where he worked on potential neuropsychopharmacological drugs and designed, synthesized, and patented (in 1969) the compound Bupropion (BW 323U66) that was approved for use as an antidepressant in 1985 and sold under the trade name Wellbutrin. Another application of the drug was as a smoking cessation aid.[4]
Selected publications
- Mehta, N B (1983), "The Chemistry of Bupropion", The Journal of Clinical Psychiatry (May 1983) 44 (5), pp. 56–9, PMID 6406464
- David L. Musso, Nariman B. Mehta, Francis E. Soroko, Robert M. Ferris, Elizabeth B. Hollingsworth, Bernard T. Kenney (2004), "Synthesis and evaluation of the antidepressant activity of the enantiomers of bupropion", Chirality (Chirality, published 2004-09-21) 5 (7): 495–500, doi:10.1002/chir.530050704, PMID 8240925
- Mehta, Nariman B; Arthur P Phillips, Florence Fu Lui, Ronald E Brooks (1960), "Maleamic and citraconamic acids, methyl esters, and imides", The Journal of Organic Chemistry 25 (6): 1012–1015, doi:10.1021/jo01076a038 Cite uses deprecated parameter
|coauthors=(help)
Notes
- 1 2 "Nariman Bomanshaw Mehta: Obituary". Times-News. Burlington, North Carolina. August 23, 2014. Retrieved November 20, 2014.
- ↑ U.S. Patent 3,819,706
- ↑ Irani K.D. and Mehta N.B. (1942) "Theoretical and Practical Physics"
- ↑ van Setten, Henk. "1985: Want a Zyban?". The history of mental health. Retrieved 29 November 2014.
References
- "Dr. Nariman B. Mehta: A scientist and a chemist". Retrieved May 24, 2014.
- Schatzberg, Alan F.; Nemeroff, Charles B. (2009). The American Psychiatric Publishing Textbook of Psychopharmacology (4 ed.). American Psychiatric Publishing, Inc. p. 416. ISBN 978-1585623099.
- Wilson, Brent; Paul, Panchajanya; Mehta, Sunny; Coffey, Barbara (February 2013). "Hypokalemia Secondary to Bupropion Sustained Release Overdose". Journal of child and adolescent psychopharmacology 23 (1): 57–60. doi:10.1089/cap.2013.2313. PMC 3613169. PMID 23410142.